Paper 23 - A PHASE IA/IB, DOSE-ESCALATION/EXPANSION STUDY OF THE MDM2-P53 ANTAGONIST BRIGIMADLIN (BI 907828) IN PATIENTS WITH SOLID TUMORS: SAFETY AND EFFICACY IN PATIENTS WITH LIPOSARCOMA

Author(s)

• 

  Patrick Schöffski, MD, MPH

  Medical Oncologist
  Department of General Medical Oncology, University Hospitals Leuven, and Laboratory of Experimental Oncology, KU Leuven, Leuven Cancer Institute, Leuven, Belgium
  Leuven, Vlaams-Brabant, Belgium

  Slides

Co-Author(s)

• PL

  Patricia LoRusso, MD

  Yale University School of Medicine, Yale Cancer Center
  New Haven, Connecticut, United States
• NY

  Noboru Yamamoto, MD

  Department of Experimental Therapeutics, National Cancer Center Hospital
  Tokyo, Tokyo, Japan
• IL

  Iwona Lugowska, MD

  Early Phase Clinical Trials Unit, Maria Skłodowska Curie National Research Institute of Oncology
  Warsaw, Mazowieckie, Poland
• 

  Victor Moreno, PhD

  Director of START Madrid-FJD
  START Madrid-FJD, Fundación Jiménez Díaz
  Madrid, Madrid, Spain
• UL

  Ulrich M. Lauer, MD

  Department of Medical Oncology & Pneumology and Tübingen Early Phase Clinical Trials Unit, University Hospital Tübingen
  Tübingen, Baden-Wurttemberg, Germany
• CH

  Chenxiao Hu, MD

  Boehringer Ingelheim Pharmaceuticals Inc.
  Ridgefield, Connecticut, United States
• SD

  Sara Durland-Busbice, MD

  Boehringer Ingelheim Pharmaceuticals Inc.
  Ridgefield, Connecticut, United States
• GJ

  Girish Jayadeva, MD

  Boehringer Ingelheim Pharmaceuticals Inc.
  Ridgefield, Connecticut, United States
• 

  Mehdi Lahmar, MD (he/him/his)

  Clinical Program Leader
  Boehringer Ingelheim International GmbH
  mainz, Rheinland-Pfalz, Germany
• MG

  Mrinal Gounder, MD

  Memorial Sloan Kettering Cancer Center
  New York, New York, United States